Monday, December 11, 2017 1:52:08 PM
BY MarketWatch
— 5:03 PM ET 12/04/2017
DepoMed Inc.
) announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. ( COLL ) to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed
) said that it would take royalties as Collegium markets and sells Nucynta, and eliminate its painkiller salesforce and any brand advertising for the product. The company plans to lay off 40% of its workforce, about 70 employees, and move its headquarters out of Newark, California, to a state on the East Coast or in the Midwest. "Taking these steps, in terms of headcount reductions and office relocation, will provide additional financial and strategic benefits," DepoMed
) Chief Executive Arthur Higgins,who took the reins of the company earlier this year after an activist-investor battle (http:// www.marketwatch.com/story/depomed-dives-as-activist-investor-fight-leads-to-new-ceo-board-members-2017-03-28), said in a prepared statement. DepoMed
) will receive a minimum royalty of $135 million a year while cutting $70 million in annual expenses, the company said. Through nine months of this year, DepoMed
) has reported $183.3 million in Nucynta sales, more than half of its $286.3 million in total revenue. DepoMed
) and Collegium shares were both halted for a little more than a half-hour in late trading ahead of the announcement; after trading resumed, DepoMed ( DEPO ) shares, which were down more than 60% on the year, gained nearly 5% and Collegium shares added about 0.4%.
Any posts are just an opinion and should not be taken as investment advice. Always do your own DD
Recent COLL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 08:32:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 02:39:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 02:06:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:52:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/06/2024 03:53:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 08:47:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 12:03:46 PM
- Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2024 12:00:00 PM
- Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/15/2024 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 06:41:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 08:34:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:04:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:01:35 PM
- Collegium Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 10:02:38 AM
- Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology • GlobeNewswire Inc. • 07/29/2024 10:00:00 AM
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:05:25 PM
- Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise • GlobeNewswire Inc. • 06/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 08:50:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:06:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:36:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 09:22:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 05:59:12 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM